What is the price to sales ratio of Evogene?

Evogene Ltd’s capital turnover — a measure of revenue relative to shareholder’s equity — is better than only 9.71% of US listed stocks. EVGN’s price/sales ratio is 126.65; that’s higher than the P/S ratio of 96.77% of US stocks.

What kind of company is Evogene Ltd.?

Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company today announced that it will hold virtual investor and analyst days, in both Hebrew and English, via Zoom webinars.

When is Evogene going to release its results?

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for the first quarter of 2021 on Wednesday, May 26th, 2021. Mr.

What is the price to sales ratio of evgn?

EVGN’s price/sales ratio is 126.65; that’s higher than the P/S ratio of 96.77% of US stocks. As for revenue growth, note that EVGN’s revenue has grown -84.1% over the past 12 months; that beats the revenue growth of only 2.01% of US companies in our set.

Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company today announced that it will hold virtual investor and analyst days, in both Hebrew and English, via Zoom webinars.

Who is the chairman of the Board of Evogene?

Mr. Martin S. Gerstel serves as the Chairman of the Board of Directors of Evogene since 2004, is a director and co-founder of Itamar Medical, a medical device company, and director of MazeBolt Technologies, a cyber security company.

What is the price to sales ratio of Evogene?